Search

Your search keyword '"Broere F"' showing total 122 results
Start Over Author "Broere F" Database OAIster
122 results on '"Broere F"'

1. The catabolic-to-anabolic shift seen in the canine osteoarthritic cartilage treated with knee joint distraction occurs after the distraction period

Author

Chirurgie, CS_Locomotion, Interne geneeskunde GD, Immunologie, CS_Welfare & emerging diseases, Teunissen, M., Meij, B.P., Snel, L., Coeleveld, K., Popov-Celeketic, J., Ludwig, I.S., Broere, F., Lafeber, F.P.J.G., Tryfonidou, M.A., Mastbergen, S.C., Chirurgie, CS_Locomotion, Interne geneeskunde GD, Immunologie, CS_Welfare & emerging diseases, Teunissen, M., Meij, B.P., Snel, L., Coeleveld, K., Popov-Celeketic, J., Ludwig, I.S., Broere, F., Lafeber, F.P.J.G., Tryfonidou, M.A., and Mastbergen, S.C.

Published
2023

2. The catabolic-to-anabolic shift seen in the canine osteoarthritic cartilage treated with knee joint distraction occurs after the distraction period

Author

Chirurgie, CS_Locomotion, Interne geneeskunde GD, Immunologie, CS_Welfare & emerging diseases, Infectious Diseases and Immunology - Immunology, Locomotion - Surgery (CA), Teunissen, M., Meij, B.P., Snel, L., Coeleveld, K., Popov-Celeketic, J., Ludwig, I.S., Broere, F., Lafeber, F.P.J.G., Tryfonidou, M.A., Mastbergen, S.C., Chirurgie, CS_Locomotion, Interne geneeskunde GD, Immunologie, CS_Welfare & emerging diseases, Infectious Diseases and Immunology - Immunology, Locomotion - Surgery (CA), Teunissen, M., Meij, B.P., Snel, L., Coeleveld, K., Popov-Celeketic, J., Ludwig, I.S., Broere, F., Lafeber, F.P.J.G., Tryfonidou, M.A., and Mastbergen, S.C.

Published
2023

3. The catabolic-to-anabolic shift seen in the canine osteoarthritic cartilage treated with knee joint distraction occurs after the distraction period

Author

Poli REU, Regenerative Medicine and Stem Cells, Lab Reumatologie/Klinische Immunologie, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Teunissen, M., Meij, B. P., Snel, L., Coeleveld, K., Popov-Celeketic, J., Ludwig, I. S., Broere, F., Lafeber, F. P.J.G., Tryfonidou, M. A., Mastbergen, S. C., Poli REU, Regenerative Medicine and Stem Cells, Lab Reumatologie/Klinische Immunologie, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Teunissen, M., Meij, B. P., Snel, L., Coeleveld, K., Popov-Celeketic, J., Ludwig, I. S., Broere, F., Lafeber, F. P.J.G., Tryfonidou, M. A., and Mastbergen, S. C.

Published
2023

7. Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies

Author

Lord, P., Spiering, R., Aguillon, J.C., Anderson, A.E., Appel, S., Benitez-Ribas, D., Brinke, A. Ten, Broere, F., Cools, N., Cuturi, M.C., Diboll, J., Geissler, E.K., Giannoukakis, N., Gregori, S., Ham, S.M. van, Lattimer, S., Marshall, L., Harry, R.A., Hutchinson, J.A., Isaacs, J.D., Joosten, I., Kooten, C. van, Cerio, A. Lopez Diaz de, Nikolic, T., Oral, H.B., Sofronic-Milosavljevic, L., Ritter, T., Riquelme, P., Thomson, A.W., Trucco, M., Vives-Pi, M., Martinez-Caceres, E.M., Hilkens, C.M., Lord, P., Spiering, R., Aguillon, J.C., Anderson, A.E., Appel, S., Benitez-Ribas, D., Brinke, A. Ten, Broere, F., Cools, N., Cuturi, M.C., Diboll, J., Geissler, E.K., Giannoukakis, N., Gregori, S., Ham, S.M. van, Lattimer, S., Marshall, L., Harry, R.A., Hutchinson, J.A., Isaacs, J.D., Joosten, I., Kooten, C. van, Cerio, A. Lopez Diaz de, Nikolic, T., Oral, H.B., Sofronic-Milosavljevic, L., Ritter, T., Riquelme, P., Thomson, A.W., Trucco, M., Vives-Pi, M., Martinez-Caceres, E.M., and Hilkens, C.M.

Abstract

Contains fulltext : 167331.pdf (publisher's version ) (Open Access), Cellular therapies with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation. The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. Here we describe an initiative by members of the tolAPC field to generate a minimum information model for tolAPC (MITAP), providing a reporting framework that will make differences and similarities between tolAPC products transparent. In this way, MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application.

Published
2016

8. Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies

Author

Lord, P., Spiering, R., Aguillon, J.C., Anderson, A.E., Appel, S., Benitez-Ribas, D., Brinke, A. Ten, Broere, F., Cools, N., Cuturi, M.C., Diboll, J., Geissler, E.K., Giannoukakis, N., Gregori, S., Ham, S.M. van, Lattimer, S., Marshall, L., Harry, R.A., Hutchinson, J.A., Isaacs, J.D., Joosten, I., Kooten, C. van, Cerio, A. Lopez Diaz de, Nikolic, T., Oral, H.B., Sofronic-Milosavljevic, L., Ritter, T., Riquelme, P., Thomson, A.W., Trucco, M., Vives-Pi, M., Martinez-Caceres, E.M., Hilkens, C.M., Lord, P., Spiering, R., Aguillon, J.C., Anderson, A.E., Appel, S., Benitez-Ribas, D., Brinke, A. Ten, Broere, F., Cools, N., Cuturi, M.C., Diboll, J., Geissler, E.K., Giannoukakis, N., Gregori, S., Ham, S.M. van, Lattimer, S., Marshall, L., Harry, R.A., Hutchinson, J.A., Isaacs, J.D., Joosten, I., Kooten, C. van, Cerio, A. Lopez Diaz de, Nikolic, T., Oral, H.B., Sofronic-Milosavljevic, L., Ritter, T., Riquelme, P., Thomson, A.W., Trucco, M., Vives-Pi, M., Martinez-Caceres, E.M., and Hilkens, C.M.

Abstract

Contains fulltext : 167331.pdf (publisher's version ) (Open Access), Cellular therapies with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation. The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. Here we describe an initiative by members of the tolAPC field to generate a minimum information model for tolAPC (MITAP), providing a reporting framework that will make differences and similarities between tolAPC products transparent. In this way, MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application.

Published
2016

9. Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies

Author

Lord, P., Spiering, R., Aguillon, J.C., Anderson, A.E., Appel, S., Benitez-Ribas, D., Brinke, A. Ten, Broere, F., Cools, N., Cuturi, M.C., Diboll, J., Geissler, E.K., Giannoukakis, N., Gregori, S., Ham, S.M. van, Lattimer, S., Marshall, L., Harry, R.A., Hutchinson, J.A., Isaacs, J.D., Joosten, I., Kooten, C. van, Cerio, A. Lopez Diaz de, Nikolic, T., Oral, H.B., Sofronic-Milosavljevic, L., Ritter, T., Riquelme, P., Thomson, A.W., Trucco, M., Vives-Pi, M., Martinez-Caceres, E.M., Hilkens, C.M., Lord, P., Spiering, R., Aguillon, J.C., Anderson, A.E., Appel, S., Benitez-Ribas, D., Brinke, A. Ten, Broere, F., Cools, N., Cuturi, M.C., Diboll, J., Geissler, E.K., Giannoukakis, N., Gregori, S., Ham, S.M. van, Lattimer, S., Marshall, L., Harry, R.A., Hutchinson, J.A., Isaacs, J.D., Joosten, I., Kooten, C. van, Cerio, A. Lopez Diaz de, Nikolic, T., Oral, H.B., Sofronic-Milosavljevic, L., Ritter, T., Riquelme, P., Thomson, A.W., Trucco, M., Vives-Pi, M., Martinez-Caceres, E.M., and Hilkens, C.M.

Abstract

Contains fulltext : 167331.pdf (publisher's version ) (Open Access), Cellular therapies with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation. The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. Here we describe an initiative by members of the tolAPC field to generate a minimum information model for tolAPC (MITAP), providing a reporting framework that will make differences and similarities between tolAPC products transparent. In this way, MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application.

Published
2016

10. Mesenchymal stem cell therapy in proteoglycan induced arthritis

Author

Infection & Immunity, Risk Assessment, dI&I RA-I&I I&I, LS Immunologie, Swart, J. F., de Roock, S., Hofhuis, F. M., Rozemuller, H., van den Broek, T., Moerer, P., Broere, F., van Wijk, F., Kuis, W., Prakken, B. J., Martens, a.c.m, Wulffraat, N. M., Infection & Immunity, Risk Assessment, dI&I RA-I&I I&I, LS Immunologie, Swart, J. F., de Roock, S., Hofhuis, F. M., Rozemuller, H., van den Broek, T., Moerer, P., Broere, F., van Wijk, F., Kuis, W., Prakken, B. J., Martens, a.c.m, and Wulffraat, N. M.

Published
2015

11. Mesenchymal stem cell therapy in proteoglycan induced arthritis

Author

Infection & Immunity, Risk Assessment, dI&I RA-I&I I&I, LS Immunologie, Swart, J. F., de Roock, S., Hofhuis, F. M., Rozemuller, H., van den Broek, T., Moerer, P., Broere, F., van Wijk, F., Kuis, W., Prakken, B. J., Martens, a.c.m, Wulffraat, N. M., Infection & Immunity, Risk Assessment, dI&I RA-I&I I&I, LS Immunologie, Swart, J. F., de Roock, S., Hofhuis, F. M., Rozemuller, H., van den Broek, T., Moerer, P., Broere, F., van Wijk, F., Kuis, W., Prakken, B. J., Martens, a.c.m, and Wulffraat, N. M.

Published
2015

12. Mesenchymal stem cell therapy in proteoglycan induced arthritis

Author

Infection & Immunity, Risk Assessment, dI&I RA-I&I I&I, LS Immunologie, Swart, J. F., de Roock, S., Hofhuis, F. M., Rozemuller, H., van den Broek, T., Moerer, P., Broere, F., van Wijk, F., Kuis, W., Prakken, B. J., Martens, a.c.m, Wulffraat, N. M., Infection & Immunity, Risk Assessment, dI&I RA-I&I I&I, LS Immunologie, Swart, J. F., de Roock, S., Hofhuis, F. M., Rozemuller, H., van den Broek, T., Moerer, P., Broere, F., van Wijk, F., Kuis, W., Prakken, B. J., Martens, a.c.m, and Wulffraat, N. M.

Published
2015

13. Autologous Stem Cell Transplantation Restores Immune Tolerance in Experimental Arthritis by Renewal and Modulation of the Teff Cell Compartment

Author

Strategic Infection Biology, Dep Infectieziekten Immunologie, I&I RATIA-SIB, Delemarre, E.M., Roord, S.T.A., van den Broek, T., Zonneveld - Huijssoon, E., de Jager, W., Rozemuller, H., Martens, A.C.M., Broere, F., Wulffraat, N.M., Glant, T., Prakken, B.J., van Wijk, F., Strategic Infection Biology, Dep Infectieziekten Immunologie, I&I RATIA-SIB, Delemarre, E.M., Roord, S.T.A., van den Broek, T., Zonneveld - Huijssoon, E., de Jager, W., Rozemuller, H., Martens, A.C.M., Broere, F., Wulffraat, N.M., Glant, T., Prakken, B.J., and van Wijk, F.

Published
2014

14. Activated Peritoneal Cavity B-1a Cells Posses Regulatory B Cell Properties

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, Dep Infectieziekten Immunologie, I&I RATIA-SIB, Margry, B., Kersemakers, S.C.W., Hoek, A., Arkesteijn, G.J.A., Wieland, W.H., van Eden, W., Broere, F., Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, Dep Infectieziekten Immunologie, I&I RATIA-SIB, Margry, B., Kersemakers, S.C.W., Hoek, A., Arkesteijn, G.J.A., Wieland, W.H., van Eden, W., and Broere, F.

Published
2014

15. Activated Peritoneal Cavity B-1a Cells Posses Regulatory B Cell Properties

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, I&I RATIA-SIB, Dep Infectieziekten Immunologie, Margry, B., Kersemakers, S.C.W., Hoek, A., Arkesteijn, G.J.A., Wieland, W.H., van Eden, W., Broere, F., Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, I&I RATIA-SIB, Dep Infectieziekten Immunologie, Margry, B., Kersemakers, S.C.W., Hoek, A., Arkesteijn, G.J.A., Wieland, W.H., van Eden, W., and Broere, F.

Published
2014

16. Autologous Stem Cell Transplantation Restores Immune Tolerance in Experimental Arthritis by Renewal and Modulation of the Teff Cell Compartment

Author

Strategic Infection Biology, Dep Infectieziekten Immunologie, I&I RATIA-SIB, Delemarre, E.M., Roord, S.T.A., van den Broek, T., Zonneveld - Huijssoon, E., de Jager, W., Rozemuller, H., Martens, A.C.M., Broere, F., Wulffraat, N.M., Glant, T., Prakken, B.J., van Wijk, F., Strategic Infection Biology, Dep Infectieziekten Immunologie, I&I RATIA-SIB, Delemarre, E.M., Roord, S.T.A., van den Broek, T., Zonneveld - Huijssoon, E., de Jager, W., Rozemuller, H., Martens, A.C.M., Broere, F., Wulffraat, N.M., Glant, T., Prakken, B.J., and van Wijk, F.

Published
2014

17. Autologous Stem Cell Transplantation Restores Immune Tolerance in Experimental Arthritis by Renewal and Modulation of the Teff Cell Compartment

Author

Strategic Infection Biology, Dep Infectieziekten Immunologie, I&I RATIA-SIB, Delemarre, E.M., Roord, S.T.A., van den Broek, T., Zonneveld - Huijssoon, E., de Jager, W., Rozemuller, H., Martens, A.C.M., Broere, F., Wulffraat, N.M., Glant, T., Prakken, B.J., van Wijk, F., Strategic Infection Biology, Dep Infectieziekten Immunologie, I&I RATIA-SIB, Delemarre, E.M., Roord, S.T.A., van den Broek, T., Zonneveld - Huijssoon, E., de Jager, W., Rozemuller, H., Martens, A.C.M., Broere, F., Wulffraat, N.M., Glant, T., Prakken, B.J., and van Wijk, F.

Published
2014

18. Activated Peritoneal Cavity B-1a Cells Posses Regulatory B Cell Properties

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, I&I RATIA-SIB, Dep Infectieziekten Immunologie, Margry, B., Kersemakers, S.C.W., Hoek, A., Arkesteijn, G.J.A., Wieland, W.H., van Eden, W., Broere, F., Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, I&I RATIA-SIB, Dep Infectieziekten Immunologie, Margry, B., Kersemakers, S.C.W., Hoek, A., Arkesteijn, G.J.A., Wieland, W.H., van Eden, W., and Broere, F.

Published
2014

20. Mycobacterial and mouse HSP70 have immuno-modulatory effects on dendritic cells

Author

Spiering, R., van der Zee, R., Wagenaar, J.A., van Eden, W., Broere, F., Spiering, R., van der Zee, R., Wagenaar, J.A., van Eden, W., and Broere, F.

Abstract

Previously, it has been shown that heat shock protein 70 (HSP70) can prevent inflammatory damage in experimental autoimmune disease models. Various possible underlying working mechanisms have been proposed. One possibility is that HSP70 induces a tolerogenic phenotype in dendritic cells (DCs) as a result of the direct interaction of the antigen with the DC. Tolerogenic DCs can induce antigen-specific regulatory T cells and dampen pathogenic T cell responses. We show that treatment of murine DCs with either mycobacterial (Mt) or mouse HSP70 and pulsed with the disease-inducing antigen induced suppression of proteoglycan-induced arthritis (PGIA), although mouse HSP70-treated DCs could ameliorate PGIA to a greater extent. In addition, while murine DCs treated with Mt- or mouse HSP70 had no significantly altered phenotype as compared to untreated DCs, HSP70-treated DCs pulsed with pOVA (ovalbumin peptide 323–339) induced a significantly increased production of IL-10 in pOVA-specific T cells. IL-10-producing T cells were earlier shown to be involved in Mt HSP70-induced suppression of PGIA. In conclusion, this study indicates that Mt- and mouse HSP70-treated BMDC can suppress PGIA via an IL-10-producing T cell-dependent manner.

Published
2013

21. The Role of Natural Killer Cells in Autoimmunity

Author

Boer, C.G., Broere, F. (Thesis Advisor), Jansen, C.A., Boer, C.G., Broere, F. (Thesis Advisor), and Jansen, C.A.

Abstract

Autoimmune diseases are characterized by the selective attack or destruction of a single cell type or tissue by auto-reactive cells of the immune system. The cause of attack of cells is due to loss of self-tolerance of cells like T and B cells which are part of the adaptive immune system. These cells are the major cause of pathology in autoimmunity disorders like type-1 diabetes and rheumatoid arthritis (1,2). Most autoimmune disorders are characterized by sites of chronic inflammation (3,4). In addition to T and B cells, other immune cells like natural killer (NK) cells are also present in the target organs (5-7). NK cells are lymphocytes of the innate immune system, with potent effector functions. NK cells can directly lyse target cells, produce cytokines and interact with other immune cells like DC and T cells (8-10). These functions of NK cells can contribute to autoimmunity either by protecting against or enhancing autoimmunity. NK cells could target and kill auto-reactive T-cells, but NK cells could also recruit auto-reactive T-cells to sites of infection (1,11). The levels of circulating NK cells are lower in patients with autoimmune disorders and have a reduced function (12-15). This reduced function might contribute to autoimmune disorders, by preventing NK cells to functions as that these cells normally would. The reduced function of NK cells, lower numbers and that NK cells are found in the target organs, suggests that NK cells may contribute to autoimmune disorders. The nature of NK cell function in autoimmunity is not clear; NK cells can protect against or enhance autoimmunity. Thus what is the nature of NK cell function in autoimmune diseases and could NK cell function be manipulated to prevent or treat autoimmune diseases? The aim of this review is to discuss the role of NK cells in autoimmune diseases and their use as potential drug targets. The first focus will be on NK cells function under healthy conditions and how self-tolerance is maintained. Ne

Published
2013

23. Mycobacterial and mouse HSP70 have immuno-modulatory effects on dendritic cells

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, Dep Infectieziekten Immunologie, Spiering, R., van der Zee, R., Wagenaar, J.A., van Eden, W., Broere, F., Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, Dep Infectieziekten Immunologie, Spiering, R., van der Zee, R., Wagenaar, J.A., van Eden, W., and Broere, F.

Published
2013

24. Stress proteins are used by the immune system for cognate interactions with anti-inflammatory regulatory T cells

Author

Advances in Veterinary Medicine, Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Faculteit Diergeneeskunde, van Eden, W., van Herwijnen, M.J.C., Wagenaar, J, van Kooten, P., Broere, F., van der Zee, R., Advances in Veterinary Medicine, Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Faculteit Diergeneeskunde, van Eden, W., van Herwijnen, M.J.C., Wagenaar, J, van Kooten, P., Broere, F., and van der Zee, R.

Published
2013

25. PLGA nanoparticles enhance the expression of retinaldehyde dehydrogenase enzymes in dendritic cells and induce FoxP3(+) T-cells in vitro.

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Keijzer, C., Spiering, R., Silva, A.L., van Eden, W., Jiskoot, W., Vervelde, L., Broere, F., Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Keijzer, C., Spiering, R., Silva, A.L., van Eden, W., Jiskoot, W., Vervelde, L., and Broere, F.

Published
2013

27. Peritoneal cavity B-1a cells promote peripheral CD4(+) T-cell activation.

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, Dep Infectieziekten Immunologie, Margry, B., Wieland, W.H., van Kooten, P., van Eden, W., Broere, F., Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, Dep Infectieziekten Immunologie, Margry, B., Wieland, W.H., van Kooten, P., van Eden, W., and Broere, F.

Published
2013

28. Tandem repeats modify the structure of the canine CD1D gene

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Geneeskunde van gezelschapsdieren, Dep Infectieziekten Immunologie, Looringh van Beeck, F.A., Leegwater, P.A.J., Herrmann, T., Broere, F., Rutten, V.P.M.G., Willemse, T., van Rhijn, I., Risk Assessment of Toxic and Immunomodulatory Agents, Geneeskunde van gezelschapsdieren, Dep Infectieziekten Immunologie, Looringh van Beeck, F.A., Leegwater, P.A.J., Herrmann, T., Broere, F., Rutten, V.P.M.G., Willemse, T., and van Rhijn, I.

Published
2013

29. APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4+ CD25+ T cells from peripheral blood of rheumatoid arthritis patients

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Barberá, A., Lorenzo, N., Mazola, Y., Falcón, V., Torres, A.M., Hernández, M.I., Hernández, M.V., Margry, B., de Groot, A.M., van Roon, J.A.G., van der Zee, R., Broere, F., van Eden, W., Padrón, G., Domínguez, M.D.C., Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Barberá, A., Lorenzo, N., Mazola, Y., Falcón, V., Torres, A.M., Hernández, M.I., Hernández, M.V., Margry, B., de Groot, A.M., van Roon, J.A.G., van der Zee, R., Broere, F., van Eden, W., Padrón, G., and Domínguez, M.D.C.

Published
2013

30. APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4+ CD25+ T cells from peripheral blood of rheumatoid arthritis patients

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Barberá, A., Lorenzo, N., Mazola, Y., Falcón, V., Torres, A.M., Hernández, M.I., Hernández, M.V., Margry, B., de Groot, A.M., van Roon, J.A.G., van der Zee, R., Broere, F., van Eden, W., Padrón, G., Domínguez, M.D.C., Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Barberá, A., Lorenzo, N., Mazola, Y., Falcón, V., Torres, A.M., Hernández, M.I., Hernández, M.V., Margry, B., de Groot, A.M., van Roon, J.A.G., van der Zee, R., Broere, F., van Eden, W., Padrón, G., and Domínguez, M.D.C.

Published
2013

33. Stress proteins are used by the immune system for cognate interactions with anti-inflammatory regulatory T cells

Author

Advances in Veterinary Medicine, Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Faculteit Diergeneeskunde, van Eden, W., van Herwijnen, M.J.C., Wagenaar, J, van Kooten, P., Broere, F., van der Zee, R., Advances in Veterinary Medicine, Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Faculteit Diergeneeskunde, van Eden, W., van Herwijnen, M.J.C., Wagenaar, J, van Kooten, P., Broere, F., and van der Zee, R.

Published
2013

34. Mycobacterial and mouse HSP70 have immuno-modulatory effects on dendritic cells

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, Dep Infectieziekten Immunologie, Spiering, R., van der Zee, R., Wagenaar, J.A., van Eden, W., Broere, F., Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, Dep Infectieziekten Immunologie, Spiering, R., van der Zee, R., Wagenaar, J.A., van Eden, W., and Broere, F.

Published
2013

35. PLGA nanoparticles enhance the expression of retinaldehyde dehydrogenase enzymes in dendritic cells and induce FoxP3(+) T-cells in vitro

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Keijzer, C., Spiering, R., Silva, A.L., van Eden, W., Jiskoot, W., Vervelde, L., Broere, F., Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Keijzer, C., Spiering, R., Silva, A.L., van Eden, W., Jiskoot, W., Vervelde, L., and Broere, F.

Published
2013

36. Peritoneal cavity B-1a cells promote peripheral CD4(+) T-cell activation.

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, Dep Infectieziekten Immunologie, Margry, B., Wieland, W.H., van Kooten, P., van Eden, W., Broere, F., Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, Dep Infectieziekten Immunologie, Margry, B., Wieland, W.H., van Kooten, P., van Eden, W., and Broere, F.

Published
2013

37. Tandem repeats modify the structure of the canine CD1D gene

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Geneeskunde van gezelschapsdieren, Dep Infectieziekten Immunologie, Looringh van Beeck, F.A., Leegwater, P.A.J., Herrmann, T., Broere, F., Rutten, V.P.M.G., Willemse, T., van Rhijn, I., Risk Assessment of Toxic and Immunomodulatory Agents, Geneeskunde van gezelschapsdieren, Dep Infectieziekten Immunologie, Looringh van Beeck, F.A., Leegwater, P.A.J., Herrmann, T., Broere, F., Rutten, V.P.M.G., Willemse, T., and van Rhijn, I.

Published
2013

38. Tandem repeats modify the structure of the canine CD1D gene

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Geneeskunde van gezelschapsdieren, Dep Infectieziekten Immunologie, Looringh van Beeck, F.A., Leegwater, P.A.J., Herrmann, T., Broere, F., Rutten, V.P.M.G., Willemse, T., van Rhijn, I., Risk Assessment of Toxic and Immunomodulatory Agents, Geneeskunde van gezelschapsdieren, Dep Infectieziekten Immunologie, Looringh van Beeck, F.A., Leegwater, P.A.J., Herrmann, T., Broere, F., Rutten, V.P.M.G., Willemse, T., and van Rhijn, I.

Published
2013

39. APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4+ CD25+ T cells from peripheral blood of rheumatoid arthritis patients

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Barberá, A., Lorenzo, N., Mazola, Y., Falcón, V., Torres, A.M., Hernández, M.I., Hernández, M.V., Margry, B., de Groot, A.M., van Roon, J.A.G., van der Zee, R., Broere, F., van Eden, W., Padrón, G., Domínguez, M.D.C., Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Barberá, A., Lorenzo, N., Mazola, Y., Falcón, V., Torres, A.M., Hernández, M.I., Hernández, M.V., Margry, B., de Groot, A.M., van Roon, J.A.G., van der Zee, R., Broere, F., van Eden, W., Padrón, G., and Domínguez, M.D.C.

Published
2013

40. Stress proteins are used by the immune system for cognate interactions with anti-inflammatory regulatory T cells

Author

Advances in Veterinary Medicine, Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Faculteit Diergeneeskunde, van Eden, W., van Herwijnen, M.J.C., Wagenaar, J, van Kooten, P., Broere, F., van der Zee, R., Advances in Veterinary Medicine, Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Faculteit Diergeneeskunde, van Eden, W., van Herwijnen, M.J.C., Wagenaar, J, van Kooten, P., Broere, F., and van der Zee, R.

Published
2013

41. Peritoneal cavity B-1a cells promote peripheral CD4(+) T-cell activation.

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, Dep Infectieziekten Immunologie, Margry, B., Wieland, W.H., van Kooten, P., van Eden, W., Broere, F., Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, Dep Infectieziekten Immunologie, Margry, B., Wieland, W.H., van Kooten, P., van Eden, W., and Broere, F.

Published
2013

43. PLGA nanoparticles enhance the expression of retinaldehyde dehydrogenase enzymes in dendritic cells and induce FoxP3(+) T-cells in vitro

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Keijzer, C., Spiering, R., Silva, A.L., van Eden, W., Jiskoot, W., Vervelde, L., Broere, F., Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Keijzer, C., Spiering, R., Silva, A.L., van Eden, W., Jiskoot, W., Vervelde, L., and Broere, F.

Published
2013

45. Mycobacterial and mouse HSP70 have immuno-modulatory effects on dendritic cells

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, Dep Infectieziekten Immunologie, Spiering, R., van der Zee, R., Wagenaar, J.A., van Eden, W., Broere, F., Risk Assessment of Toxic and Immunomodulatory Agents, Strategic Infection Biology, Dep Infectieziekten Immunologie, Spiering, R., van der Zee, R., Wagenaar, J.A., van Eden, W., and Broere, F.

Published
2013

46. The Role of Natural Killer Cells in Autoimmunity

Author

Boer, C.G., Broere, F. (Thesis Advisor), Jansen, C.A., Boer, C.G., Broere, F. (Thesis Advisor), and Jansen, C.A.

Abstract

Autoimmune diseases are characterized by the selective attack or destruction of a single cell type or tissue by auto-reactive cells of the immune system. The cause of attack of cells is due to loss of self-tolerance of cells like T and B cells which are part of the adaptive immune system. These cells are the major cause of pathology in autoimmunity disorders like type-1 diabetes and rheumatoid arthritis (1,2). Most autoimmune disorders are characterized by sites of chronic inflammation (3,4). In addition to T and B cells, other immune cells like natural killer (NK) cells are also present in the target organs (5-7). NK cells are lymphocytes of the innate immune system, with potent effector functions. NK cells can directly lyse target cells, produce cytokines and interact with other immune cells like DC and T cells (8-10). These functions of NK cells can contribute to autoimmunity either by protecting against or enhancing autoimmunity. NK cells could target and kill auto-reactive T-cells, but NK cells could also recruit auto-reactive T-cells to sites of infection (1,11). The levels of circulating NK cells are lower in patients with autoimmune disorders and have a reduced function (12-15). This reduced function might contribute to autoimmune disorders, by preventing NK cells to functions as that these cells normally would. The reduced function of NK cells, lower numbers and that NK cells are found in the target organs, suggests that NK cells may contribute to autoimmune disorders. The nature of NK cell function in autoimmunity is not clear; NK cells can protect against or enhance autoimmunity. Thus what is the nature of NK cell function in autoimmune diseases and could NK cell function be manipulated to prevent or treat autoimmune diseases? The aim of this review is to discuss the role of NK cells in autoimmune diseases and their use as potential drug targets. The first focus will be on NK cells function under healthy conditions and how self-tolerance is maintained. Ne

Published
2013

47. The anti-inflammatory mechanisms of Hsp70

Author

Borges, T.J., Wieten, L., van Herwijnen, M.J.C., Broere, F., van der Zee, R., Bonorino, C., van Eden, W., Borges, T.J., Wieten, L., van Herwijnen, M.J.C., Broere, F., van der Zee, R., Bonorino, C., and van Eden, W.

Published
2012

50. Tolerogenic dendritic cells that inhibit autoimmune arthritis can be induced by a combination of carvacrol and thermal stress

Author

Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Spiering, R., van der Zee, R., Wagenaar, J.P.A., Kapetis, F., Zolezzi, F., van Eden, W., Broere, F., Risk Assessment of Toxic and Immunomodulatory Agents, Dep Infectieziekten Immunologie, Spiering, R., van der Zee, R., Wagenaar, J.P.A., Kapetis, F., Zolezzi, F., van Eden, W., and Broere, F.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results